NVS
Novartis AG NYSE Listed Nov 7, 1996$145.37
Mkt Cap $277.4B
52w Low $104.93
61.7% of range
52w High $170.46
50d MA $153.03
200d MA $138.01
P/E (TTM)
20.2x
EV/EBITDA
12.7x
P/B
6.1x
Debt/Equity
0.8x
ROE
—
P/FCF
15.1x
RSI (14)
—
ATR (14)
—
Beta
0.52
50d MA
$153.03
200d MA
$138.01
Avg Volume
2.3M
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Lichtstrasse 35 · Basel, V8 4056 · CH
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | BMO | 2.11 | 1.99 | -5.7% | 144.19 | +0.0% | +0.9% | -1.8% | +3.4% | -0.9% | -1.3% | — |
| Feb 4, 2026 | BMO | 1.99 | 2.03 | +2.0% | 149.86 | +2.6% | +2.0% | +0.7% | +1.6% | +0.4% | +0.7% | — |
| Oct 28, 2025 | BMO | 2.26 | 2.25 | -0.4% | 129.14 | -2.8% | -4.4% | -1.3% | +0.7% | +1.0% | +0.1% | — |
| Jul 17, 2025 | BMO | 2.38 | 2.42 | +1.7% | 118.37 | -2.3% | -3.3% | -0.2% | -0.1% | +2.4% | +1.0% | — |
| Apr 29, 2025 | BMO | 2.12 | 2.28 | +7.5% | 112.63 | +0.7% | +0.7% | +0.0% | -1.9% | +2.7% | -1.1% | — |
| Jan 31, 2025 | BMO | 1.80 | 1.98 | +10.0% | 104.75 | +1.4% | -0.0% | +0.7% | -0.0% | +4.1% | -2.6% | — |
| Oct 29, 2024 | BMO | 1.94 | 2.06 | +6.2% | 115.63 | -3.3% | -4.4% | -0.6% | -1.4% | +0.9% | +1.1% | — |
| Jul 18, 2024 | BMO | 1.89 | 1.97 | +4.2% | 111.80 | -3.6% | -4.1% | -1.0% | +2.4% | -0.9% | +1.5% | — |
| Apr 23, 2024 | BMO | 1.73 | 1.80 | +4.0% | 95.12 | +3.8% | +2.3% | +1.1% | +0.7% | -1.6% | -0.4% | — |
| Jan 31, 2024 | BMO | 1.64 | 1.53 | -6.7% | 107.75 | -2.0% | -4.0% | +1.8% | -1.5% | -0.2% | +0.3% | — |
| Oct 24, 2023 | BMO | 1.70 | 1.74 | +2.4% | 94.69 | -0.2% | +0.2% | +0.5% | -1.2% | -2.2% | +1.6% | — |
| Jul 18, 2023 | BMO | 1.68 | 1.83 | +8.9% | 93.62 | +2.9% | +4.6% | -0.2% | +1.9% | -0.1% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | Morgan Stanley | Maintains | Overweight → Overweight | — | $150.75 | $149.67 | -0.7% | -0.7% | -1.0% | +1.5% | +1.6% | +1.5% |
| Jan 6 | Barclays | Upgrade | Underweight → Equal Weight | — | $137.91 | $139.09 | +0.9% | +3.2% | -0.2% | -0.4% | +0.1% | +0.2% |
| Dec 8 | JP Morgan | Upgrade | Neutral → Overweight | — | $132.16 | $132.83 | +0.5% | -1.5% | +0.6% | +0.1% | +0.9% | +0.2% |
| Sep 12 | Goldman Sachs | Downgrade | Neutral → Sell | — | $127.70 | $123.86 | -3.0% | -2.8% | -0.7% | -0.4% | -0.3% | -0.1% |
| Feb 13 | UBS | Downgrade | Buy → Neutral | — | $107.00 | $106.96 | -0.0% | +0.7% | -2.1% | +1.1% | +0.3% | +0.4% |
| Nov 19 | Erste Group | Downgrade | Buy → Hold | — | $103.04 | $102.58 | -0.4% | +0.2% | -0.2% | +0.7% | +0.4% | -0.7% |
| Oct 30 | BMO Capital | Maintains | Market Perform → Market Perform | — | $110.53 | $110.63 | +0.1% | -0.6% | -1.4% | +0.9% | +1.1% | -1.0% |
| Sep 11 | BofA Securities | Downgrade | Buy → Neutral | — | $116.99 | $114.98 | -1.7% | -1.5% | +0.4% | -0.1% | +1.1% | -1.1% |
| Sep 5 | Goldman Sachs | Downgrade | Buy → Neutral | — | $119.38 | $117.74 | -1.4% | -2.4% | +0.1% | +0.4% | -0.1% | -1.5% |
| Sep 3 | Jefferies | Downgrade | Buy → Hold | — | $120.89 | $119.13 | -1.5% | -2.0% | +0.7% | -2.4% | +0.1% | +0.4% |
| Jul 2 | Jefferies | Maintains | Buy → Buy | — | $106.54 | $106.32 | -0.2% | -0.1% | +0.3% | +1.3% | -0.1% | +0.2% |
| Apr 24 | BMO Capital | Maintains | Market Perform → Market Perform | — | $97.28 | $98.50 | +1.3% | +1.1% | +0.7% | -1.6% | -0.4% | +0.0% |
| Sep 25 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $95.71 | $95.41 | -0.3% | +0.7% | -0.4% | -1.1% | +2.1% | -0.5% |
| May 9 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $81.21 | $80.06 | -1.4% | -2.7% | +1.1% | -0.4% | +1.6% | +0.5% |
| Dec 6 | Exane BNP Paribas | Downgrade | Outperform → Neutral | — | $75.70 | $75.96 | +0.3% | +0.7% | +0.2% | +0.8% | -1.1% | +0.3% |
| Dec 3 | Bryan Garnier | Downgrade | Buy → Neutral | — | $75.65 | $76.29 | +0.8% | +0.1% | +0.7% | +0.2% | +0.8% | -1.1% |
| Sep 20 | Deutsche Bank | Downgrade | Hold → Sell | — | $78.99 | $77.65 | -1.7% | -0.8% | +0.3% | -0.3% | +0.9% | -0.8% |
| Mar 10 | Argus | Downgrade | Buy → Hold | — | $79.05 | $79.97 | +1.2% | +0.8% | +0.7% | -0.7% | +1.4% | +0.8% |
| Feb 1 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $85.61 | $85.85 | +0.3% | -0.8% | -0.2% | -0.3% | +1.4% | -0.1% |
| Sep 1 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $81.44 | $83.17 | +2.1% | +0.9% | +2.3% | -2.0% | -0.5% | +0.8% |
| Feb 25 | Guggenheim Securities | Downgrade | Buy → Neutral | — | $85.24 | $85.70 | +0.5% | -2.4% | -0.9% | -1.2% | -2.4% | +3.5% |
| Feb 25 | Guggenheim | Downgrade | Buy → Neutral | — | $85.24 | $85.70 | +0.5% | -2.4% | -0.9% | -1.2% | -2.4% | +3.5% |
| Apr 25 | Guggenheim | Upgrade | Neutral → Buy | — | $73.64 | $75.23 | +2.2% | +3.6% | +0.9% | -0.2% | +1.4% | -0.4% |
| Apr 10 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $78.93 | $77.74 | -1.5% | -1.8% | -0.1% | -2.0% | +0.9% | -2.0% |
| Nov 26 | Cowen & Co. | Upgrade | Market Perform → Outperform | — | $73.65 | $74.14 | +0.7% | +1.1% | -0.1% | +1.0% | +1.4% | +0.5% |
| Nov 19 | Goldman Sachs | Upgrade | Neutral → Conviction Buy | — | $73.42 | $73.83 | +0.6% | +0.6% | -1.5% | +2.4% | -1.1% | +1.1% |
| Sep 11 | Citigroup | Upgrade | Neutral → Buy | — | $69.05 | $70.20 | +1.7% | +1.7% | +0.6% | +1.0% | -0.1% | -0.1% |
| Sep 10 | BofA Securities | Upgrade | Underperform → Buy | — | $68.42 | $69.12 | +1.0% | +0.9% | +1.7% | +0.6% | +1.0% | -0.1% |
| Sep 10 | Bank of America | Upgrade | Underperform → Buy | — | $68.42 | $69.12 | +1.0% | +0.9% | +1.7% | +0.6% | +1.0% | -0.1% |
| Jul 19 | Barclays | Upgrade | Underweight → Equal Weight | — | $67.74 | $67.79 | +0.1% | -0.2% | +1.8% | -0.0% | +0.3% | +0.5% |
| May 29 | HSBC | Downgrade | Buy → Hold | — | $63.67 | $62.80 | -1.4% | -1.5% | +1.0% | -1.6% | +1.4% | +0.2% |
| May 25 | Credit Suisse | Upgrade | Underperform → Neutral | — | $63.73 | $64.15 | +0.7% | -0.1% | -1.5% | +1.0% | -1.6% | +1.4% |
| May 5 | Argus | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Jan 25 | Leerink Swann | Maintains | Market Perform → Market Perform | — | $76.50 | $77.88 | +1.8% | +2.4% | +0.3% | -1.0% | -1.4% | -1.8% |
| Oct 25 | Barclays | Downgrade | Equal Weight → Underweight | — | $69.55 | $69.21 | -0.5% | -2.1% | -0.6% | -0.2% | +1.3% | +1.0% |
| Oct 23 | Leerink Swann | Maintains | Market Perform → Market Perform | — | $71.73 | $72.14 | +0.6% | +0.2% | -3.2% | -2.1% | -0.6% | -0.2% |
| Jul 26 | Morgan Stanley | Upgrade | Underweight → Overweight | — | $70.45 | $70.80 | +0.5% | +0.8% | +0.1% | -0.3% | +0.5% | +0.2% |
| Jul 5 | Credit Suisse | Downgrade | Neutral → Underperform | — | $69.94 | $68.72 | -1.7% | -0.6% | -1.4% | +0.4% | -0.3% | -0.1% |
| Apr 5 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $62.56 | $62.10 | -0.7% | -1.3% | -0.1% | +0.0% | -0.3% | +0.6% |
| Jan 11 | Credit Suisse | Downgrade | Outperform → Neutral | — | $62.00 | $61.39 | -1.0% | -1.9% | +0.1% | -0.5% | -0.6% | -0.1% |
| Jan 3 | JP Morgan | Downgrade | Overweight → Neutral | — | $60.94 | $60.98 | +0.1% | -0.0% | -0.3% | +2.0% | -0.8% | +0.9% |
| Nov 10 | Argus | Upgrade | Hold → Buy | — | $62.16 | $61.73 | -0.7% | -0.3% | -0.8% | -2.0% | -0.2% | +0.4% |
| Apr 12 | Morgan Stanley | Downgrade | Equal Weight → Underperform | — | $62.84 | $62.47 | -0.6% | +0.1% | +0.3% | +0.8% | -0.6% | +0.9% |
| Apr 1 | UBS | Downgrade | Buy → Neutral | — | $60.61 | $58.49 | -3.5% | -1.4% | +1.9% | -0.2% | +3.5% | -0.3% |
| Mar 29 | Citigroup | Downgrade | Buy → Neutral | — | $61.18 | $59.90 | -2.1% | -1.0% | +0.3% | -0.1% | -1.4% | +1.9% |
| Mar 23 | Leerink Swann | Downgrade | Outperform → Market Perform | — | $62.24 | $62.63 | +0.6% | -0.6% | -0.8% | -0.2% | -1.0% | +0.3% |
| Jul 27 | Leerink Swann | Maintains | Outperform → Outperform | — | $85.17 | $85.74 | +0.7% | -0.3% | +1.2% | +0.9% | -0.5% | +0.5% |
| Jun 22 | Bryan Garnier | Upgrade | Neutral → Buy | — | $83.82 | $85.20 | +1.6% | +1.9% | +0.6% | -1.1% | -0.8% | -0.9% |
| Mar 4 | Natixis | Upgrade | Neutral → Buy | — | $82.88 | $82.32 | -0.7% | -0.0% | -0.1% | -1.5% | +0.5% | -1.8% |
| Jan 5 | Cowen & Co. | Upgrade | Market Perform → Outperform | — | $77.18 | $78.17 | +1.3% | +0.2% | -0.8% | +0.4% | +3.5% | +0.9% |
No insider trades available.
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Novartis's acquisition of Atrium Therapeutics closed at $72.00 per share, providing value to optionholders whose stock options exceeded the exercise price.
Feb 27
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Atrium Therapeutics completed a spin-off from its parent company, creating an independent entity focused on its therapeutic pipeline with separate ownership structure and operational autonomy.
Feb 26
8-K · 7.01
! Medium
Atrium Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Avidity Biosciences plans to distribute all Atrium Therapeutics shares pro rata to its stockholders, creating a spinoff that will give Avidity investors direct ownership in the independent company.
Feb 26
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Novartis's acquisition of Atrium Therapeutics (RNA) through Avidity Biosciences is progressing toward shareholder vote, with the definitive proxy statement filed January 30, 2026.
Feb 23
8-K · 5.02
!!! Very High
Tarsus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Tarsus Pharmaceuticals appointed David E.I. Pyott as a Class III director, adding experienced leadership to its board governance.
Feb 18
8-K · 5.02
!!! Very High
Entera Bio Ltd. -- 8-K 5.02: Executive Change
Entera Bio Ltd. appointed Geno J. Germano as Class III director effective February 4, 2026, strengthening board governance and potentially signaling strategic direction changes.
Feb 9
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
This filing appears to contain standard forward-looking statement disclaimers rather than material news, providing limited actionable information for investors regarding Atrium Therapeutics' operations or financial condition.
Feb 3
Data updated apr 26, 2026 4:20pm
· Source: massive.com